Written By: Monica Mioduszewski Published: April 16, 2026 Contents Introduction How many animals are used in research? Which animals are used for testing? Why animal models remain in use Limitations of Animal Models New Approach Methodologies (NAMs): potential solutions to animal testing A persistent challenge: antibody generation Polyclonal Antibody Sequencing [...]
Rapid Novor Technical Note | REpAb Platform Series Authors: Chelsea Reitzel, Thierry Le Bihan Published: April 7, 2026 Contents Abstract Key Findings Background Decision Framework: Which Scenario Applies to You? Methods Results and Discussion Inter-Laboratory Titer Harmonization (Scenario C) Practical Workflow Summary Conclusion Abstract [...]
April 7, 2026 Rapid Novor Inc., developer of EasyM®, a blood-based test for minimal residual disease (MRD) in multiple myeloma, has completed enrollment of 70 patients in a Canadian prospective study assessing the test’s clinical utility in newly diagnosed multiple myeloma (NDMM). Conducted in collaboration with Princess Margaret Cancer Centre (PMCC) and funded by [...]
March 10, 2026 Rapid Novor Inc., a Canadian biotechnology leader, announced today that its diagnostic laboratory has received a provisional license from the Ontario Ministry of Health (MOH) for its EasyM® assay, enabling the company to begin testing patients in Canada. This milestone represents the first time highly sensitive measurable residual disease (MRD) monitoring [...]
In this webinar, you will learn: How to select the appropriate bispecific antibody format based on your target and functional intent. How to apply the various manufacturing and protein engineering approaches to overcome bispecific complexity. How high-confidence monoclonal antibody sequencing enables reproducible bispecific design. Building Bispecific Antibodies with Confidence Bispecific [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications